Bharat Biotech AND Covaxin
Bharat Biotech applied for ‘Emergency Use Authorization’
The developer of indigenous COVID-19 vaccine, Bharat
Biotech, has applied to the central drug regulator (DCGI) and asked the permission
of emergency use authorization for its vaccine called COVAXIN.
HIGHLIGHTS
·
The Bharat Biotech which is a Hyderabad based firm has
become the third applicant to apply for the approval of emergency use of
COVID-19 vaccine.
·
Other two firm that has applied for emergency use Authorization
include-the Serum Institute of India and Pfizer.
COVAXIN
·
COVAXIN is India’s indigenously developed vaccine.
·
It has been developed by Bharat Biotech.
·
Vaccine was developed in collaboration with Indian council
of Medical Research (ICMR).
·
This vaccine is currently undergoing the phase 3 of
the trails.
·
The trail are being conducted at 18 cities in India on
over 22 thousand volunteers.
What
does ‘Emergency Use ‘Authorization ’ mean?
Emergency use approval for a drug is granted only
after there is sufficient evidence suggesting that the medical product is safe
and effective. However, the final approval is granted only after completion of
the trails and by proper analysis of full data.
Background
The Indian arm of Pfizer has also asked for the
emergency use approval for its vaccine. The vaccine of Pfizer was co-developed
with BioNTech in the United States.
Pfizer has already has got the emergency usage
clearance in the UK and Bahrain. The other firm that is Serum institute, also
applied for approval of Oxford COVID-19 vaccine COVISHIELD. The COVISHIELD vaccine has been developed in
collaboration with the pharma Company AstraZenece and Oxford Univercity.
Comments
Post a Comment
if you have any doubt, please let me know